Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

NCT07535359 | Unknown

• 1 other identifier: DS7300-0001-EAP-MA
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.

Conditions

SCLC; Extensive-stage Small Cell Lung Cancer

Keywords

Ifinatamab Deruxtecan; Medical Access Program; 3L+ SCLC; DS7300a; I-DXd; Extensive-stage small cell lung cancer

Interventions

Ifinatamab Deruxtecan DRUG

12 mg/kg intravenous infusion Q3W (on Day 1 of each 21-day cycle)

Also known as: DS7300a, I-DXd

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient has at least one SCLC lesion that has not been previously irradiated.
• The patient is aged ≥18 years or older.
• The patient has histologically or cytologically documented ES-SCLC.
• The patient had prior therapy with platinum-based chemotherapy and one additional treatment as systemic therapy for extensive-stage disease.
• The patient has received prior treatment with a minimum of two previous lines of systemic therapy.
• The patient has a documented radiological disease progression on or after the most recent systemic therapy.
• The patient has an ECOG PS of 0-1.
• The patient has a life expectancy of ≥3 months
• The patient has adequate organ and bone marrow function as defined in the protocol within 7 days prior to Cycle 1 Day 1 of I-DXd treatment. Transfusion (red blood cell or platelet) or granulocyte-colony stimulating factor (G-CSF) administration is not allowed within 2 weeks prior to screening laboratory tests.
• Male and female patients of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the program and for at least 8 months for females and 5 months for males after the last dose of I-DXd.
• Female patients of childbearing potential must have a negative serum pregnancy test within 3 days prior to enrolment.
• Female patients agree to not donate, or retrieve for their own use, ova throughout the participation in the MAP and for 8 months following the last dose of I-DXd. Preservation of ova may be considered prior to enrolment in this program.
• Male patients are surgically sterile or willing to use highly effective birth control throughout the participation in the MAP and for 5 months following the last dose of I DXd.
• Male patients agree not to freeze or donate sperm throughout participation in the MAP and for 5 months following the last dose of I-DXd. Preservation of sperm may be considered prior to enrolment in this program.
• Patients who meet any of the following criteria will not be eligible for the Medical Access Program.

You may not qualify if:

• The Patient is eligible for other treatment options or can enroll in an open clinical trial with patients with pre-treated ES-SCLC.
• The patient has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
• The patient has been discontinued from an ADC that consists of an exatecan derivative (e.g., trastuzumab deruxtecan) due to treatment-related toxicities.
• The patient has had an inadequate washout period before randomization as defined in the protocol.
• The patient has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
• The patient has experienced any of the following events within the past 6 months:
• cerebrovascular accident, or
• transient ischemic attack, or
• another arterial thromboembolic event.
• The patient has a clinically significant corneal disease.
• The patient has uncontrolled or significant cardiovascular disease as defined in the protocol.
• The patient has any history of ILD/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening.
• The patient has a clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses as defined in the protocol.
• The patient is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/COPD), topical steroids (for mild skin conditions), or intra-articular steroid injections.
• The patient has a history of allogeneic bone marrow, stem cell, or solid organ transplant.

Sponsors & Collaborators

• Daiichi Sankyo: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (3)

Central Care Cancer Center

Salina, Kansas, 67401, United States

AVAILABLE

Duke Cancer Institute

Durham, North Carolina, 27710, United States

AVAILABLE

University of Texas Southwestern Medical

Dallas, Texas, 75390, United States

AVAILABLE

MeSH Terms

Conditions

Small Cell Lung Carcinoma

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Global Oncology Medical Affairs

  Daiichi Sankyo

  STUDY DIRECTOR

Central Study Contacts

Contact for Program Information

CONTACT

908-992-6400; patient.access@bionicalemas.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2026
• First Posted: April 17, 2026
• Last Updated: May 6, 2026

Record last verified: 2026-05

Locations

US (3)